PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
van Zyl, D.G.* ; Mautner, J. ; Delecluse, H.-J.*

Progress in EBV vaccines.

Front. Oncol. 9:104 (2019)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
The Epstein-Barr virus (EBV) is a ubiquitous pathogen that imparts a significant burden of disease on the human population. EBV is the primary cause of infectious mononucleosis and is etiologically linked to the development of numerous malignancies. In recent years, evidence has also been amassed that strongly implicate EBV in the development of several autoimmune diseases, including multiple sclerosis. Prophylactic and therapeutic vaccination has been touted as a possible means of preventing EBV infection and controlling EBV-associated diseases. However, despite several decades of research, no licensed EBV vaccine is available. The majority of EBV vaccination studies over the last two decades have focused on the major envelope protein gp350, culminating in a phase II clinical trial that showed soluble gp350 reduced the incidence of IM, although it was unable to protect against EBV infection. Recently, novel vaccine candidates with increased structural complexity and antigenic content have been developed. The ability of next generation vaccines to safeguard against B-cell and epithelial cell infection, as well as to target infected cells during all phases of infection, is likely to decrease the negative impact of EBV infection on the human population.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.137
1.158
33
44
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Ebv (epstein-barr Virus) ; Lympho Proliferative Disorder ; Oncogenic ; Vaccine ; γ-herpesvirus; Epstein-barr-virus; T-cell Responses; Phase-i Trial; Envelope Glycoprotein Gp340; Ephrin Receptor A2; Infectious-mononucleosis; Cottontop Tamarins; Recombinant Vaccinia; Monoclonal-antibodies; Persistent Infection
Sprache englisch
Veröffentlichungsjahr 2019
HGF-Berichtsjahr 2019
ISSN (print) / ISBN 2234-943X
e-ISSN 2234-943X
Zeitschrift Frontiers in Oncology
Quellenangaben Band: 9, Heft: , Seiten: , Artikelnummer: 104 Supplement: ,
Verlag Frontiers
Verlagsort Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Gene Vector (AGV)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-501500-001
DOI 10.3389/fonc.2019.00104
WOS ID WOS:000459689300001
Scopus ID 85063295135
PubMed ID 30859093
Erfassungsdatum 2019-03-21
[➜Korrektur melden]